Liquidia (NASDAQ:LQDA) Now Covered by HC Wainwright

Research analysts at HC Wainwright initiated coverage on shares of Liquidia (NASDAQ:LQDA) in a research report issued to clients and investors on Friday, Benzinga reports. The firm set a “buy” rating and a $76.00 price target on the stock. HC Wainwright‘s price target indicates a potential upside of 30.76% from the company’s current price.

LQDA has been the subject of a number of other research reports. Zacks Research downgraded Liquidia from a “hold” rating to a “strong sell” rating in a research report on Tuesday, September 22nd. Bank of America set a $54.00 target price on Liquidia and gave the company a “neutral” rating in a research note on Wednesday. Wedbush set a $58.00 target price on Liquidia in a research report on Friday, October 2nd. Piper Sandler set a $129.00 price target on shares of Liquidia in a research note on Friday, July 24th. Finally, Needham & Company LLC boosted their price target on shares of Liquidia from $58.00 to $66.00 and gave the company a “buy” rating in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Liquidia currently has a consensus rating of “Hold” and a consensus target price of $75.23.

Liquidia Trading Up 5.3%

Shares of Liquidia stock opened at $58.12 on Friday. The company’s fifty day simple moving average is $49.19 and its 200-day simple moving average is $54.68. The company has a market cap of $5.24 billion, a price-to-earnings ratio of 24.98, a PEG ratio of 0.75 and a beta of 0.40. The company has a current ratio of 1.02, a quick ratio of 2.12 and a debt-to-equity ratio of 0.63. Liquidia has a 1 year low of $22.31 and a 1 year high of $93.61.

Liquidia (NASDAQ:LQDA) last released its earnings results on Tuesday, November 10th. The company reported ($2.64) EPS for the quarter, missing the consensus estimate of $0.96 by ($3.60). Liquidia had a negative net margin of 15.15% and a positive return on equity of 264.65%. The company had revenue of $225.30 million for the quarter, compared to analyst estimates of $214.18 million. During the same quarter in the previous year, the company earned ($0.04) earnings per share. Liquidia’s revenue for the quarter was up 314.9% compared to the same quarter last year. As a group, sell-side analysts expect that Liquidia will post 1.32 EPS for the current year.

Insider Transactions at Liquidia

In other Liquidia news, insider Rajeev Saggar sold 9,218 shares of the stock in a transaction on Monday, October 12th. The stock was sold at an average price of $28.48, for a total transaction of $262,528.64. Following the completion of the transaction, the insider directly owned 126,368 shares in the company, valued at $3,598,960.64. This represents a 6.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Scott Moomaw sold 8,863 shares of the stock in a transaction on Monday, October 12th. The stock was sold at an average price of $28.48, for a total value of $252,418.24. Following the transaction, the insider owned 181,487 shares of the company’s stock, valued at $5,168,749.76. This represents a 4.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 566,579 shares of company stock valued at $25,746,120. 25.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Liquidia

A number of hedge funds have recently made changes to their positions in LQDA. Bank of New York Mellon Corp bought a new position in Liquidia during the 2nd quarter valued at about $29,694,000. Bank of America Corp DE grew its stake in Liquidia by 18.7% during the first quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after buying an additional 360,372 shares during the last quarter. Public Sector Pension Investment Board grew its stake in Liquidia by 90.0% during the third quarter. Public Sector Pension Investment Board now owns 458,708 shares of the company’s stock worth $13,881,000 after buying an additional 217,332 shares during the last quarter. Eversept Partners LP increased its holdings in shares of Liquidia by 33.0% during the first quarter. Eversept Partners LP now owns 677,392 shares of the company’s stock worth $25,565,000 after buying an additional 167,949 shares in the last quarter. Finally, Seven Fleet Capital Management LP increased its holdings in shares of Liquidia by 124.5% during the first quarter. Seven Fleet Capital Management LP now owns 204,876 shares of the company’s stock worth $7,732,000 after buying an additional 113,609 shares in the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing treatments for pulmonary hypertension and other serious diseases. Its work includes inhaled therapies designed to deliver medicines to the lungs. The company’s marketed product, Yutrepia (treprostinil) inhalation powder, is approved in the United States for adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Liquidia also has a pipeline of investigational therapies, including other formulations of treprostinil.